Recent Updates
Recently added Catalysts
NVRS Positive Sentiment

Noveris Health Sciences Announces Results of 2026 Annual General and Special Meeting

Key Takeaway: Noveris Health Sciences Inc. held its annual general and special meeting on September 4, 2026, where shareholders approved all proposed resolutions. Key decisions included setting the number of directors to three and electing Jason Birmingham, Michael Callas, and Peter Field as directors. Additionally, the appointment of HDCPA Professional Corporation as auditor was approved, along with an amendment to the Company's Articles regarding quorum requirements.

Market Sentiment Analysis

POSITIVE FACTORS

  • All resolutions at the annual meeting were approved.
  • New directors elected to the board for continued governance.
  • Appointment of a professional auditor for financial oversight.
  • Approval of the Amended and Restated Omnibus Long-Term Incentive Plan.

Full Press Release Details

We use cookies to analyze user behavior in order to constantly improve the website for you. View our Privacy Policy and Terms of Use .
September 09, 2026 5:05 PM EDT | Source: Noveris Health Sciences Inc.
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the " Company " or " Noveris ") announces the results of its annual general and special meeting of shareholders held on September 4, 2026 (the "Meeting").
A total of 21,697,593 common shares of the Company were represented at the Meeting, representing approximately 37.06% of the 58,548,051 common shares issued and outstanding and entitled to vote at the Meeting.
All resolutions presented to shareholders at the Meeting were approved.
Shareholders approved setting the number of directors of the Company at three.
Shareholders elected Jason Birmingham, Michael Callas and Peter Field as directors of the Company to hold office until the next annual meeting of shareholders or until their successors are duly elected or appointed.
Shareholders approved the appointment of HDCPA Professional Corporation as auditor of the Company for the ensuing year and authorized the directors to fix the auditor's remuneration.
Shareholders approved the Company's Amended and Restated Omnibus Long-Term Incentive Plan.
Shareholders approved the special resolution authorizing an amendment to the Company's Articles to change the quorum requirements.
The Company thanks its shareholders for their participation in the Meeting and their continued support.
Noveris Health Sciences Inc. is a Canadian life sciences company focused on opportunities in mental health and therapeutic innovation. Additional information concerning the Company is available under its profile on SEDAR+ at www.sedarplus.ca and at www.noveris.health .
On behalf of the Board of Directors NOVERIS HEALTH SCIENCES INC. Jason Birmingham, Chief Executive Officer
For Further Information Tel: +1 778-900-NVRS (6877) Email: fair@noveris.health Web: www.noveris.health
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313698
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Frequently Asked Questions

When was the Noveris Health Sciences annual meeting held?

The annual meeting was held on September 4, 2026.

Who were elected as directors of Noveris Health Sciences?

Jason Birmingham, Michael Callas, and Peter Field were elected as directors.

What auditor was appointed for Noveris Health Sciences?

HDCPA Professional Corporation was appointed as the auditor.

What was approved regarding the number of directors?

Shareholders approved setting the number of directors at three.

Last updated: Sep 9, 2026